UNITED THERAPEUTICS CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 234.5 USD | +0.18% |
|
+1.20% | +6.67% |
Financials (USD)
| Sales 2024 * | 2.7B | Sales 2025 * | 2.82B | Capitalization | 11.01B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.2B | Net income 2025 * | 1.23B | EV / Sales 2024 * | 2.86 x |
| Net cash position 2024 * | 3.3B | Net cash position 2025 * | 4.14B | EV / Sales 2025 * | 2.44 x |
| P/E ratio 2024 * |
9.77
x | P/E ratio 2025 * |
9.51
x | Employees | 1,168 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 62.77% |
More Fundamentals
* Assessed data
More news
Latest transcript on United Therapeutics Corporation
More recommendations
More press releases
More news
| 1 day | -1.63% | ||
| 1 week | -0.43% | ||
| Current month | +1.89% | ||
| 1 month | -1.61% | ||
| 3 months | +8.24% | ||
| 6 months | +3.83% | ||
| Current year | +6.44% |
1 week
232.84
240.74
1 month
221.53250.89
Current year
208.62250.89
1 year
204.44261.54
3 years
158.38283.09
5 years
74.31283.09
10 years
74.31283.09
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 69 | 96-06-25 | |
| President | 52 | 11-03-31 | |
James Edgemond
DFI | Director of Finance/CFO | 56 | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Raymond Kurzweil
BRD | Director/Board Member | 76 | 01-12-31 |
| Chief Executive Officer | 69 | 96-06-25 | |
Tommy Thompson
BRD | Director/Board Member | 81 | 09-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.06% | 1 M€ | 0.00% | - | |
| 2.87% | 2 M€ | +5.19% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 234.5 | +0.18% | 403 618 |
| 24-04-22 | 234.1 | -1.63% | 552,493 |
| 24-04-19 | 237.9 | +0.42% | 616,033 |
| 24-04-18 | 236.9 | +0.69% | 476,359 |
| 24-04-17 | 235.3 | +1.52% | 372,437 |
Delayed Quote Nasdaq, April 22, 2024 at 04:00 pm EDT
More quotes
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.
Calendar
2024-04-30
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
234.1
USD
Average target price
285.5
USD
Spread / Average Target
+21.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.44% | 11.01B | |
| -0.02% | 42.11B | |
| +43.29% | 40.08B | |
| +5.04% | 40B | |
| -11.32% | 26.87B | |
| +5.25% | 24.58B | |
| -23.83% | 18.44B | |
| -1.62% | 11.94B | |
| +22.75% | 11.66B | |
| -18.61% | 9.87B |
- Stock Market
- Equities
- UTHR Stock
